Horizon Adaptive Platform
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 300 patients (estimated)
- Sponsors
- Multiple Myeloma Research Consortium
- Tags
- B-Cell Maturation Antigen (BCMA), CD3, Closed Label (Masked), Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1876
- NCT Identifier
- NCT06171685
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.